Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iprazochrome is a small molecule drug classified as an indole derivative and functions primarily as a serotonin (5-HT2D) receptor antagonist. It is used for the prophylaxis of migraine attacks and for both the treatment and prevention of diabetic retinopathy, particularly in people with type 2 diabetes. Chemically, it is a derivative of adrenochrome, itself an oxidation product of adrenaline. Iprazochrome decreases blood vessel permeability and fragility, thereby reducing migraine frequency and symptoms but not eliminating them entirely. It also neutralizes other vasoactive compounds such as bradykinin and histamine. The drug has been shown to inhibit platelet aggregation in vitro induced by arachidonate and ADP, though its antiserotonergic action is less potent than that of methysergide[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iprazochrome.